Dynamic Advisor Solutions LLC Raises Stock Position in Gilead Sciences, Inc. $GILD

Dynamic Advisor Solutions LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,991 shares of the biopharmaceutical company’s stock after purchasing an additional 6,569 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Gilead Sciences were worth $7,832,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Paulson Wealth Management Inc. raised its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. raised its stake in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the period. Davidson Trust Co. lifted its position in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 74 shares in the last quarter. Alpha Cubed Investments LLC boosted its stake in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Finally, Personal CFO Solutions LLC grew its holdings in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 82,000 shares of company stock valued at $10,641,790. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on GILD shares. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 20th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday. Finally, Daiwa Securities Group decreased their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Trading Down 2.6%

NASDAQ:GILD opened at $131.76 on Thursday. The company has a market cap of $163.59 billion, a PE ratio of -49.35 and a beta of 0.32. The business’s 50 day moving average is $129.54 and its two-hundred day moving average is $136.18. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 1.86% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the business earned $2.01 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.80 billion, above the approximately $7.40 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by double-digit HIV growth and continued momentum in Trodelvy. Gilead Q2 Earnings Beat on HIV and Trodelvy Growth
• Positive Sentiment: Management raised its HIV growth outlook to 9%-10% and lifted its 2026 base-business sales outlook to approximately $29.8 billion-$30.1 billion. Yeztugo, Gilead’s HIV PrEP treatment, generated roughly $1 billion in sales as uptake accelerated. Gilead Raises HIV Growth Outlook
• Positive Sentiment: Needham reaffirmed its Buy rating with a $170 price target, while Cantor Fitzgerald maintained Overweight and a $155 target, indicating potential upside if HIV and oncology growth continues.
• Positive Sentiment: Gilead declared its quarterly dividend of $0.82 per share, supporting the stock’s income appeal. The dividend is payable September 29 to shareholders of record September 15.
• Neutral Sentiment: Gilead’s full-year EPS outlook improved relative to consensus, but revenue guidance of $30.1 billion-$30.4 billion remained slightly below analysts’ $30.5 billion estimate, reflecting acquisition and research spending.
• Negative Sentiment: The company posted a $6.75-per-share quarterly loss versus $2.01 of earnings a year earlier. Acquisition-related charges and research-and-development costs overshadowed the operating improvement and raised concerns about deeper 2026 losses. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Veklury sales fell 81% in the quarter, prompting Gilead to lower its full-year outlook for the COVID-19 treatment and highlighting pressure from a declining product. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: AIDS Healthcare Foundation criticized Gilead’s HIV pricing and licensing policies, creating potential reputational and access-related risks in global markets. RBC maintained a Sector Perform rating with a $123 target, below the current valuation.
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction is a limited signal because it was scheduled in advance, but it may add to investor caution.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.